Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vioxx Strategy Aims To Switch Patients Up From OTC To Rx Market

Executive Summary

Merck is looking to move patients out of the over-the-counter analgesic market to the prescription COX-2 inhibitor Vioxx, Merck Human Health-The Americas President David Anstice said at Merck's annual business briefing Dec. 9 in Whitehouse Station, N.J.

You may also be interested in...



Schering Sales Force Reduction Shows “Changing Dynamics” In U.S. Market

Schering-Plough's sales force restructuring is a clear indication that the era of escalating field forces is coming to an end

Schering Sales Force Reduction Shows “Changing Dynamics” In U.S. Market

Schering-Plough's sales force restructuring is a clear indication that the era of escalating field forces is coming to an end

Celebrex Switches Create Approximately 7% of Scripts For Merck Vioxx

Switches from Celebrex to Vioxx accounted for approximately 7% of prescriptions for Merck's COX-2 inhibitor during November.

Related Content

UsernamePublicRestriction

Register

PS035348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel